Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Dallas, Texas
- Most recent report
- 10-Q, filed Aug 12, 2026
- Incorporated
- Delaware
- Filings on record
- 638 filings
- On EDGAR
- CIK 1419041
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company
Financials 8 of 41
News 8 of 103
Prospectuses and Registrations 8 of 42
- S-3/A Shelf registration statement, amended Jun 8, 2026
- S-3 Shelf registration statement Jun 2, 2026
- S-8 Registration statement for an employee plan Jun 2, 2026
- 424B5 Prospectus supplement for an offering Apr 9, 2026
- 424B5 Prospectus supplement for an offering Apr 8, 2026
- S-8 Registration statement for an employee plan Sep 30, 2025
- 424B5 Prospectus supplement for an offering Jun 25, 2025
- 424B5 Prospectus supplement for an offering Jun 24, 2025
Proxies 8 of 15
- DEF 14A Proxy statement for a shareholder vote Apr 29, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 30, 2025
- DEF 14A Proxy statement for a shareholder vote Dec 31, 2024
- DEF 14A Proxy statement for a shareholder vote Jul 30, 2024
- PRE 14A Preliminary proxy statement Jul 19, 2024
- DEFA14A Extra proxy material Sep 1, 2023
- DEFA14A Extra proxy material Aug 31, 2023
- DEFA14A Extra proxy material May 19, 2022
Ownership 8 of 334
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 13, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 13, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 12, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 11, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 7, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 7, 2026
- SCHEDULE 13G Large holder reported a passive stake Jul 28, 2026
Other 8 of 103
Everything here comes from Forte Biosciences, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.